A ngiogenesis is a very tightly controlled process, in which endothelial cells need to migrate and proliferate toward ischemic tissue. A long-known factor that provides a gradient for endothelial cells to migrate toward is vascular endothelial growth factor (VEGF). 1 Carefully titrated levels of VEGF are crucial for blood vessel development, because even the heterozygous deletion of VEGF is lethal in mice. 2 In the past decades, it has become clear that VEGF signaling is very complex, with different VEGF isoforms and VEGF receptors that tightly control endothelial cell behavior. Interestingly, although VEGF receptor 2 (kinase insert domain receptor [KDR]) is one of the main proangiogenic VEGF receptors, 3 binding of VEGF to VEGF receptor 1 (fms-related tyrosine kinase 1 [FLT1]) does not result in proangiogenic signaling, which raised the concept that FLT1 acts as a trap or decoy for VEGF. Thus, FLT1 can negatively regulate VEGF signaling, and this is of crucial importance, for instance, to keep the cornea avascular, 4 but also aids in controlling the fine balance between proangiogenic and antiangiogenic factors. To make matters more complex, FLT1 mRNA is alternatively spliced, giving rise to a membrane-bound FLT1 and secreted soluble FLT1, 5 but they both function as VEGF traps, preventing VEGF from activating KDR. In this issue of Circulation Research, Hassel et al 6 report that both isoforms of FLT1 are regulated by the microRNA (miRNA) miR-10.
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miRNAs are relatively recently discovered posttranscriptional modulators of gene expression that usually bind to the 3′ untranslated regions of their target genes and block translation of the mRNA into protein or promote the degradation of the targeted mRNA. 7 Many miRNAs have been described to play a key role in the cardiovascular system, controlling virtually all cellular processes. 8, 9 That miRNAs are of crucial importance for normal endothelial function was demonstrated with mice lacking Dicer, an enzyme essential for the biogenesis of miRNAs, which displayed impaired angiogenesis and increased levels of FLT1. 10 More recently, specific miRNAs with a role in angiogenesis have been identified, including miR-126, 11 members of the miR-17-92 cluster, 12, 13 and members of the miR-23-27-24 cluster. [14] [15] [16] The current study by the Srivastava laboratory 6 identifies that miR-10 is capable of modulating FLT1 levels, thereby affecting VEGF signaling and angiogenesis ( Figure) . With a strong focus on in vivo angiogenesis in the zebrafish model, the authors demonstrate that miR-10 is an endogenous facilitator of angiogenesis and that inhibition of miR-10 blunts the angiogenic response, opening up a possible clinical application to combat tumor angiogenesis. However, induction or overexpression of miR-10 could perhaps be used clinically to enhance angiogenesis in case of ischemia because of, for example, a myocardial infarction. Whether modulation of miR-10 expression also affects (patho)physiological angiogenesis in mammals remains to be established, but this is a crucial step if miR-10 is to be considered a potential therapeutic target. Furthermore, with therapies using antibodies against VEGF becoming the standard to attenuate tumor angiogenesis, 17 miR-10 inhibition alone or in combination with VEGF inhibition would have to be more efficient in blocking tumor growth than VEGF blockade alone.
An interesting mechanistic finding of the study is that miR-10 targets both the membrane-bound FLT1 and the soluble FLT1 isoforms, despite the fact that these splice variants contain unique 3′ untranslated regions, which illustrates the firm grip that miR-10 applies to keep FLT1 levels at bay. Additional evidence for this firm grip is provided by the observation that membrane-bound FLT1 and soluble FLT1 are also regulated by miR-10 in human endothelial cells, showing evolutionary robustness of the system. miRNAs generally modulate expression of many target genes, rather than switching expression on or off, resulting in subtle phenotypic effects that affect entire pathways. This is also the case for miR-10 and VEGF signaling, where absence of miR-10 does not completely block angiogenesis, highlighting a modulatory role of miR- 10 .
An open question that remains is how miR-10 itself is regulated in endothelial cells. The authors provide evidence that both in differentiating embryoid bodies and in zebrafish embryos, miR-10 expression is induced when endothelial differentiation starts. miR-10 is induced by laminar blood flow, in swine aortas in vivo and human endothelial cells in vitro, 18, 19 which suggests that blood flow is an endogenous activator of miR-10. However, in embryoid bodies no blood flow is present, so this cannot be the instigator of miR-10 expression, whereas fluid shear forces could contribute to the upregulation of miR-10 in developing embryos. miR-10a and miR-10b are located in a cluster of HOX genes in the mouse genome and may therefore be coregulated with HOX gene expression. Indeed, the HOX gene that contains miR-10a in an intron (HOXB3) also induces angiogenesis, further adding to the complexity of miR-10 regulation and function. 20 Furthermore, membrane-bound FLT1 and soluble FLT1 are only 2 of the undoubtedly many targets of miR-10. The other targets of miR-10 could additionally account for the proangiogenic effects of miR-10. One counterintuitive target of miR-10 is the host gene of miR-10a HOXB3, suggesting that miR-10a functions as a negative feedback regulator for HOXB3. 21 Downregulation of HOXB3, however, would putatively lead to repression of angiogenesis. Possible other targets that could contribute to the proangiogenic effects of miR-10 include HoxD10, 22 which promotes invasion of tumor cells, Bim, 23 a proapoptotic protein, and p21, 23 a cell cycle inhibitor. Posttranscriptional inhibition of these targets could potentially contribute to the proangiogenic effects of miR-10.
In summary, the study of Hassel et al 6 shows that miR-10 regulates the expression of FLT1 and thereby controls angiogenic behavior of endothelial cells in multiple model systems. Modulation of miR-10 in vivo could prove a potential novel application to induce or block therapeutic angiogenesis.
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None. Figure. miR-10 regulates the expression of membrane-bound FLT (mFLT) and soluble FLT (sFLT), thereby modulating vascular endothelial growth factor (VEGF) signaling. Left, In the absence of miR-10 or when miR-10 is inhibited, both mFLT and sFLT are highly expressed and trap VEGF so that signaling through KDR does not take place and angiogenesis is inhibited. Right, When miR-10 is present in endothelial cells, mFLT1 and sFLT1 are attenuated and VEGF can bind to and activate KDR, allowing angiogenesis to take place.
